New combination improves outcomes for small cell bladder and neuroendocrine prostate cancer patients: early stage but clinical study
/in Clinical Trial, Metastatic, Phase 1/by MaxAn add-on strategy to maximize workouts: electro stimulation works for cancer patients
/in Clinical Trial, Metastatic/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxA Phase 1 trial to keep an eye on: Thorium-227 (BAY2315497) in metastatic Castration Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxBenfo-Oxythiamine Shows Promise as a Radiosensitizer in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxPositive Phase 1 Data Supports Phase 2 of 177Lu rhPSMA-10.1 for mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxFDA Accepts New Drug Application for 3-Month Formulation of Leuprolide Mesylate for Advanced Prostate Cancer Treatment
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 30/2026 July 26, 2026
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026